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During the last 30 years there has been a dissemination of plasmid-mediated -lactamases
in  Enterobacteriaceae in Brazil. Extended spectrum -lactamases (ESBL) are widely dissem-
inated in the hospital setting and are detected in a lower frequency in the community
setting. Cefotaximases are the most frequently detected ESBL type and Klebsiella pneumoniae
is  the predominant species among ESBL producers. Klebsiella pneumoniae carbapenemase-
producing Enterobacteriaceae became widely disseminated in Brazil during the last decade
and KPC production is currently the most frequent resistance mechanism (96.2%) in car-
bapenem resistant K. pneumoniae.  To date KPC-2 is the only variant reported in Brazil.
Polymyxin B resistance in KPC-2-producing K. pneumoniae has come to an alarming rate
of  27.1% in 2015 in São Paulo, the largest city in Brazil. New Delhi metallo--lactamase was
detected in Brazil in 2013, has been reported in different Brazilian states but are not widely
disseminated. Antimicrobial resistance in Enterobacteriaceae in Brazil is a very serious prob-
lem  that needs urgent actions which includes both more strict adherence to infection control
measures and more judicious use of antimicrobials.
© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).arbapenemases
The  rise  of  extended-spectrum  -lactamasesrazil
nterobacteriaceae
he ﬁrst reports on antimicrobial resistance in Gram-negative
ods from Brazil, available at PubMed, were restricted to
ommunity-acquired infections. These reports were on sul-
adiazine resistance in Escherichia coli, Shigella and Salmonella
1,2nd dated from 1968. In 1971 chloramphenicol resistance
as reported in Salmonella Typhi detected in various Brazil-
an states3 and Shigella resistant to multiple antimicrobials
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resistance was only reported for ampicillin. Gales).
Third generation cephalosporins became available for clini-
cal use in Brazil in early 1980s. In our medical practice, we
lsevier Editora Ltda. This is an open access article under the CC
.
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Table 1 – Extended spectrum -lactamases detected in
Enterobacteriaceae in Brazil.
Enzyme Species
BES-1 Serratia marcescens9
CTX-M-1 K. pneumoniae14
CTX-M-2 Enterobacter aerogenes12,15; Enterobacter cloacae12,16;
Escherichia coli12,16–22; Klebsiella pneumoniae14,16,21,23–29;
K. oxytoca21; Morganella morganii16,21; Proteus
mirabilis8,17,21; Providencia stuartii16,21,30; Salmonella
typhimurium31; S. marcescens17
CTX-M-3 E. coli22
CTX-M-8 Citrobacter amalonaticus8; Enterobacter cloacae8; E.
aerogenes8; E. coli12,16,22; K. pneumoniae14
CTX-M-9 Citrobacter freundii16; E. cloacae10,12; E. coli10,12,16,20; K.
pneumoniae16
CTX-M-14 E. coli18,32
CTX-M-15 E. aerogenes12; E. cloacae12,33; E. coli18,22,32,34; K.
pneumoniae27,33,35
CTX-M-16 E. coli10; E. cloacae10
CTX-M-28 K. pneumoniae24; K. oxytoca21
CTX-M-59 E. aerogenes15; E. cloacae15; E. coli20,21,27; K.
pneumoniae21,23,27
CTX-M-74 E. cloacae16
CTX-M-75 P. stuartii16
CTX-M-131 P. stuartii36
GES-1 K. pneumoniae37
GES-7 K. pneumoniae38
PER-2 E. cloacae12,15
SHV-2 K. pneumoniae; E. coli22
SHV-4 K. pneumoniae39
SHV-5 E. cloacae16; E. coli16,19,21; K. pneumoniae16
SHV-12 E. aerogenes12,15; E. cloacae12,15; K. pneumoniae21,25,35
SHV-27 K. pneumoniae21,40
SHV-28 K. pneumoniae21,41
SHV-31 K. pneumoniae35
SHV-38 K.  pneumoniae35
SHV-40 K.  pneumoniae38
SHV-45 K. pneumoniae21
SHV-55 K. pneumoniae21
SHV-108 K. pneumoniae41
SHV-122 K. pneumoniae41
TEM-15 K. pneumoniae21
TEM-115 K. pneumoniae2132  b r a z i l i a n j o u r n a l o f m
have observed resistance to third-generation cephalosporins
among Enterobacteriaceae since 1985, but the ﬁrst report of
this ﬁnding in Brazilian hospitals was published only in 1994,
describing a 52% cefepime resistance rate among ceftazidime-
resistant Enterobacteriaceae.5 This was the ﬁrst published clue
on the presence of extended spectrum -lactamases (ESBLs)
in Brazil. In 1997, the ﬁrst conﬁrmation of ESBL production
in Enterobacteriaceae from Brazil came out. The authors doc-
umented the presence of ESBLs in 72 K. pneumoniae clinical
isolates, from private and public tertiary hospitals located in
Rio de Janeiro and São Paulo, by clavulanic acid inhibition. Of
note, they also reported a low susceptibility rates for amikacin
(41.4%) and gentamicin (29.6%) but all isolates were still sus-
ceptible to imipenem.6 A subsequent work, also published
in 1997, including 982 consecutive isolates from 18 hospitals,
from four different states and seven different cities, was the
ﬁrst publication that could be used to estimate the ESBL rate
among Enterobacteriaceae.  Assuming that resistance to third
generation cephalosporins was only due to ESBL production,
16% and 5% of K. pneumoniae and E. coli, respectively, would be
classiﬁed as ESBL producers at that time.7
The ﬁrst molecular studies on ESBLs from Brazil came
out in 2000, evidencing the predominance of blaCTX-M genes
and describing the CTX-M-8 enzyme in strains other than
K. pneumoniae from Rio de Janeiro.8 The same group of
researchers described the BES-1 and the CTX-M-16 enzymes in
strains from the same city.9,10 Subsequent surveillance studies
evidenced a growing ESBL production rates among Enterobacte-
riaceae collected from inpatients. In 2000, the ESBL production
rate in K. pneumoniae collected from intensive care units was
59.2%, while these rates in Enterobacter spp. and E. coli were
19.5% and 14.6%, respectively.11 The most recent study on the
diversity of ESBL types in Enterobacteriaceae isolated from Brazil
refers to 1827 isolates collected during the period between
August 2003 and March 2008 in the city of Curitiba, Paraná.
CTX-M-2 was the most frequently detected ESBL in all Entero-
bacteriaceae species, except in Enterobacter aerogenes, in which a
CTX-M-59-producing clone was predominant.12 Recent stud-
ies have reported that ESBL-producing Enterobacteriaceae are
now detected in a signiﬁcant rate in outpatients presenting
cystitis. In a public institution located in Brasilia, the ESBL pro-
duction rate in E. coli collected from July 2013 to April 2014 was
7.1%.13 When we  reviewed all publication from Brazil about
ESBLs, CTX-M-2 was the most frequently detected enzyme and
was also detected in the largest number of different Enterobac-
teriaceae species (Table 1).
Plasmid-mediated  AmpCs
FOX-5-like and CMY-2-like were the ﬁrst plasmid-mediated
AmpCs (pAmpC) reported in Brazilian isolates. Both enzymes
were detected in E. coli.42,43 The FOX-5-like encoding gene
was detected during the DNA sequencing of a 41-kb con-
jugative plasmid that harbored a qnrA gene and a class 1
integron with the aadB and catB3 gene cassettes.43 The CMY-
2-like enzyme was detected in four carbapenem-resistant
E. coli strains, which also possessed alteration in the outer
membrane proteins, isolated from a single patient.42 Dias
and colleagues studied the prevalence of pAmpC amongTEM-116 K. pneumoniae38
TEM-135 E. cloacae12
Enterobacteriaceae isolated from a teaching hospital in Rio
de Janeiro. In that study pAmpC encoding genes were not
detected and the multidrug resistance phenotype observed
in ﬁve E. coli strain was attributed to hyperexpression of
chromosomally encoded AmpC.44 Very few studies described
the frequency of pAmpCs in Enterobacteriaceae in Brazil,
although pAmpCs are of epidemiological importance, since
carbapenem resistance can occur in strains with concomi-
tant permeability alterations and pAmpC expression. A study
conducted in a public tertiary hospital from São Paulo
included 41 E. coli, ﬁve Klebsiella oxytoca, 65 Klebsiella pneumo-
niae, 18 P. mirabilis, and four Salmonella spp. detected during
the period from January and July 2006 and found a 0.75%
plasmid-mediated AmpC production rate and a single isolate
45producing a CMY-2-like enzyme was identiﬁed. The most
recent study on pAmpCs in Brazil evaluated the frequency of
plasmid-mediated AmpCs in E. coli isolated from urine cul-
tures from both outpatients and inpatients. The frequency
b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 S (2 0 1 6) 31–37 33
Table 2 – KPC-producing species detected in Brazil.
Species Location (City, State) MLST
C. freundii AL59; Duque de Caxias, RJ60; GO59; RJ59 –
E. aerogenes CE59; DF59; PE59
E. cloacae CE59; DF59; GO59; MG59; Porto Alegre, RS60,61; Rio de
Janeiro59,62
–
E. gergoviae Recife, PE63 –
E. hormaechei Rio de Janeiro64 –
E. coli BA59; DF59; MG59; Recife, PE59,65; Rio de Janeiro, RJ59,66 ST259; ST3959; ST4359; ST30559; ST47959; ST50265;
ST62959; ST63059; ST63159; ST63259
K. pneumoniae AL67; AM67; Brasília, DF67; Campo Grande, MS68,69;
CE67; ES67,70; Florianópolis, SC67,71; Franca, SP60;
GO67,70; João Pessoa, PB72; Lageado, RS73; MA67;
MG67,70; PE67,70; PI67; Porto Alegre, RS61,73,74; Recife,
PE28,56,65,67,75; Ribeirão Preto, SP26,60; Rio de Janeiro,
RJ14,60,67,76; São Paulo, SP27,77–80
ST1126,60,67,70,80; ST1367; ST1667,70; ST1767; ST1967;
ST2567,70; ST5567; ST7070; ST10170; ST13867; ST25860;
ST32367; ST34067,75; ST42370; ST43760,67,72,80; ST44270;
ST44370; ST75667; ST75767; ST75867; ST75967;
ST76067; ST83767; ST83867; ST83967; ST84067;
ST84167; ST84267; ST85567
K. oxytoca Recife, PE81; RJ59; MG59 –
K. georgiana Porto Alegre, PA82 –
M. morganii MG59 –
P. agglomerans RJ59 –
P. mirabilis Recife, PE83 –
P. stuartii Recife, PE84; MG59 –
S. marcescens Duque de Caxias, RJ60; Porto Alegre, RS61; Recife,
PE59,85; Dourados, MS52
–
The following abbreviations correspond to Brazilan States: AL, Alagoas; AM, Amazonas; BA, Bahia; DF, Distrito Federal; ES, Espírito Santo; GO,
B, Par
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Santa Catarina; SP, São Paulo.
f plasmid-mediated AmpC was 0.46% in outpatients and
.8% in inpatients. The full nucleotide sequences were deter-
ined and blaCMY-2 was the most frequently detected gene,
ut blaCMY-4 was also detected.46
he  rise  of  carbapenemases  in  Brazil
mipenem has been available for clinical use in Brazil since
he end of the 80s. In 1989 a surveillance study, carried
ut with 1231 isolates, mainly from inpatients from ﬁve dif-
erent medical centers from São Paulo, Rio de Janeiro and
alvador, reported a 1% imipenem resistance rate for E. coli,
hile this rate was 6% for Enterobacter sp. but resistant iso-
ates were also found among K. pneumoniae.47 In 1998, a
efpirome susceptibility study also reported imipenem resis-
ance in Enterobacteriaceae.  Using commercial microdilution
lates, 349 Enterobacteriaceae from tertiary hospitals from four
ifferent states were evaluated.48 Imipenem resistance rate
mong Enterobacter species varied from 2 to 8%, while this rate
mong K. pneumoniae was 7%, but unfortunately, no further
tudies were published on those strains. In 2005, almost 20
ears after the introduction of carbapenems in clinical use in
razil, the ﬁrst report of an Enterobacteriaceae producing a car-
apenemase came out. The work of Lincopan et al. described
he presence of IMP-1 in a K. pneumoniae strain detected in a
atient from a university hospital from São Paulo, located at
he Southeast of Brazil.49 The same IMP-1-producing K. pneu-
oniae strain was detected in six distinct hospitals of the city
f São Paulo between the years 2003 and 2005.50 In one of these
ospitals, it was responsible for causing an outbreak in an
ntensive care unit.51 IMP-1 was also detected in a P. rettgeri
solate that was co-producer of CTX-M-like, and SHV-like.50aíba; PE, Pernambuco; RJ, Rio de Janeiro; RS, Rio Grande do Sul; SC,
The co-production of IMP-10 and KPC-2 was detected in S.
marcescens causing an outbreak in a tertiary, teaching hospital
in Dourados, MS.52
GES-5, an enzyme of the GES family with spectrum toward
carbapenems, was initially detected in Brazil in a K. pneumoniae
isolated from a rectal surveillance swab of an elderly patient
admitted to a private hospital in São Paulo, in 2008. This isolate
also showed deletions on ompK35 and ompK36 genes.53 GES-5
was also detected in three genetically related Kluyvera inter-
media that were isolated from one sink and two  distinct taps
of an intensive care unit of a tertiary-care hospital in Porto
Alegre, in May 2013, during an environmental surveillance for
NDM-1-producing isolates.54 Although only reported in 2014,
GES-5 was also recovered from the blood of an adult patient
admitted to a university hospital in Porto Alegre, in 2011. The
patient had acute myeloid leukemia and had recent exposure
to multiple antibiotics.55
The ﬁrst report on the detection of Klebsiella pneumoniae
carbapenemase (KPC) in Brazil was published in 2009,56 and
described the detection of KPC-2 in 2006, ten years after the
ﬁrst detection of KPC-2 in world, in 1996, in North Carolina,
in the United States of America.57,58 The work described the
detection of KPC-2 in K. pneumoniae in four patients from the
city of Recife, located at the Northeast of Brazil. Earlier dissem-
ination of KPC-2 production was later reported in São Paulo.
Subsequently, KPC-2 was described in many  Enterobacteriaceae
species and locations all over Brazil (Table 2). To date this is
the only variant reported from Brazil, although 23 variants
(http://www.ncbi.nlm.nih.gov/pathogens/beta-lactamase-
data-resources/) have been described worldwide.
KPC-2-producing Enterobacteriaceae are now disseminated
all over Brazil but K. pneumoniae is the most frequent species.
Among this species, ST11 and ST437, which belong to the
 i c r o
r34  b r a z i l i a n j o u r n a l o f m
clonal complex 258, are the most frequently detected clonal
groups (Table 2). A recent publication analyzed 3085 K. pneumo-
niae isolates cultivated from patients from 10 private hospitals
from the great São Paulo urban area, during the period from
January 2011 to December 2015. Most of the isolates were
recovered from blood cultures. The work showed an amazing
increase in the carbapenem resistance rate, from 6.8% in 2011
to 35.5% in 2015; of note, KPC-2 was detected in 96.2% of the
carbapenem-resistant isolates, and there were both interhos-
pital and intrahospital clonal dissemination.80
New Delhi metallo--lactamase (NDM) was ﬁrstly detected
in Brazil in 2013, in Providencia rettgeri, from a patient from
Porto Alegre, a city located at the South of Brazil.86 This detec-
tion occurred four years after the initial detection in a ST14
K. pneumoniae strain causing urinary tract infection and in
an E. coli strain from feces from a Swedish patient of Indian
origin.87 Compared to what happened with KPC, which was
detected in Brazil 10 years after the initial description, NDM-1-
producing strains were detected much earlier, which indicates
a great potential for more  efﬁcient dissemination in Brazil.
This P. rettgeri strain was later shown to have heterogeneous
carbapenem resistance, which could make its detection a
challenging task.88 Subsequently, expression of NDM-1 was
reported in E. hormaechei from the same city where the ﬁrst
case had been detected.89 E. cloacae complex strains and Mor-
ganella morganii expressing NDM-1 were also reported by other
research group from Porto Alegre.90 In the same year of 2013,
the ﬁrst complete nucleotide sequences of blaNDM-1-bearing
plasmids from Brazil were described, in E. coli and E. hor-
maechei cultured from the same rectal swab from a patient
from Rio de Janeiro who  had never been exposed to carbapen-
ems. The blaNDM-1 gene was found to be located on a IncFIIk
in E. hormaechei and on a IncX3 plasmid in a ST2 E. coli, but
both plasmids contained a new structure designated Tn3000,
that could possibly mediate the transposition of the blaNDM-1
gene.91 Subsequently, coproduction of NDM-1 and KPC-2 was
described in P. rettgeri and E. cloacae from Rio de Janeiro.62,64
More  recently, a new class A carbapenemase, designated
Brazilian Klebsiella carbapenemase (BKC-1) was described in
Brazil.92 To date it has only been found in K. pneumoniae in a
low frequency, possible due to the fact that the blaBKC-1 gene is
located in a small transferable, non-conjugative plasmid.92,93
Polymyxin  resistance  in  carbapenem-resistant
K. pneumoniae:  a  nightmare
The ﬁrst report on polymyxin-resistance in Brazilian Entero-
bacteriaceae came out in 2006.94 At that time, with a low
colistin and polymyxin B clinical use, the polymyxin B resis-
tance rate was 0.5% in E. coli,  1.8% in K. pneumoniae and
16.7% in Enterobacter spp. In a subsequent publication the
same group evidenced a 3.0% resistance rate among K. pneu-
moniae in Latin America.95 In 2013, Pereira et al. reported
a 15% polymyxin resistance rate among KPC-producing K.
pneumoniae from diverse Brazilian states.67 Polymyxin resis-
tance in E. cloacae and K. pneumoniae strains was also reported
from Porto Alegre, south of Brazil.61,96 To date, interruption
of mgrB gene by insertion sequences or missense mutations
is the most frequent mechanism of polymyxin resistance in b i o l o g y 4 7 S (2 0 1 6) 31–37
K. pneumoniae in Brazil.93,97 The most recent evidence of the
amazing polymyxin resistance problem in Brazil came from a
report from São Paulo, the largest city in Latin America. The
authors described a 35.5% carbapenem resistance rate due to
KPC-2 production, among K. pneumoniae causing infections in
2015, and also found an increase in polymyxin B resistance
among KPC-producing K. pneumoniae, from 0% in 2011 to 27.1%
in 2015.80 This increase coincided with the increased use of
polymyxins as empiric therapy to treat severe infectious when
Gram negatives are possible etiologic agents in intensive care
units. More  concerning was ﬁnding interhospital and intra-
hospital clonal dissemination and the fact that most isolates
included in the study were detected from blood cultures. This
is a therapeutic nightmare, since intravenous fosfomycin and
ceftazidime-avibactam are still not available in Brazil.
Recently, the mcr-1 (mobile colistin resistance) gene was
detected in a clinical strain of E. coli ST101 from the Northeast
of Brazil.98 The authors found the gene located on a IncX4
plasmid, and consequently the selective pressure represented
by the overuse of polymyxins could have contributed to the
dissemination of this resistance mechanism.
In summary, antimicrobial resistance in Enterobacteriaceae
in Brazil is a very serious problem that needs urgent actions
which includes more  strict adherence to infection control
measures, more  judicious use of antimicrobials in human
and animal husbandries and fast approval of old and new
antimicrobials like fosfomycin and ceftazidime-avibactam for
clinical use in Brazil, in order to decrease the polymyxin con-
sume. If these measures are not applied together, the release
of ceftazidime-avibactam will be a partial measure that will
be probably followed by dissemination of NDM-1 producers in
Brazil.
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